Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology-Reference-Cited by-同舟云学术

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Published:2020-04 Issue:4 Volume:18 Page:452-478
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Gradishar William J.¹,Anderson Benjamin O.²,Abraham Jame³,Aft Rebecca⁴,Agnese Doreen⁵,Allison Kimberly H.⁶,Blair Sarah L.⁷,Burstein Harold J.⁸,Dang Chau⁹,Elias Anthony D.¹⁰,Giordano Sharon H.¹¹,Goetz Matthew P.¹²,Goldstein Lori J.¹³,Isakoff Steven J.¹⁴,Krishnamurthy Jairam¹⁵,Lyons Janice³,Marcom P. Kelly¹⁶,Matro Jennifer¹⁷,Mayer Ingrid A.¹⁸,Moran Meena S.¹⁹,Mortimer Joanne²⁰,O'Regan Ruth M.²¹,Patel Sameer A.¹³,Pierce Lori J.²²,Rugo Hope S.²³,Sitapati Amy⁷,Smith Karen Lisa²⁴,Smith Mary Lou²⁵,Soliman Hatem²⁶,Stringer-Reasor Erica M.²⁷,Telli Melinda L.⁶,Ward John H.²⁸,Young Jessica S.²⁹,Burns Jennifer L.³⁰,Kumar Rashmi³⁰

Affiliation:

1. 1Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

2. 2Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

3. 3Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

4. 4Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

5. 5The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

6. 6Stanford Cancer Institute;

7. 7UC San Diego Moores Cancer Center;

8. 8Dana-Farber/Brigham and Women’s Cancer Center;

9. 9Memorial Sloan Kettering Cancer Center;

10. 10University of Colorado Cancer Center;

11. 11The University of Texas MD Anderson Cancer Center;

12. 12Mayo Clinic Cancer Center;

13. 13Fox Chase Cancer Center;

14. 14Massachusetts General Hospital Cancer Center;

15. 15Fred & Pamela Buffet Cancer Center;

16. 16Duke Cancer Institute;

17. 17Abramson Cancer Center at the University of Pennsylvania;

18. 18Vanderbilt-Ingram Cancer Center;

19. 19Yale Cancer Center/Smilow Cancer Hospital;

20. 20City of Hope National Medical Center;

21. 21University of Wisconsin Carbone Cancer Center;

22. 22University of Michigan Rogel Cancer Center;

23. 23UCSF Helen Diller Family Comprehensive Cancer Center;

24. 24The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

25. 25Research Advocacy Network;

26. 26Moffitt Cancer Center;

27. 27O'Neal Comprehensive Cancer Center at UAB;

28. 28Huntsman Cancer Institute at the University of Utah;

29. 29Roswell Park Comprehensive Cancer Center; and

30. 30National Comprehensive Cancer Network

Abstract

Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor biology (hormone-receptor status and HER2-status). The NCCN Guidelines specific to the workup and treatment of patients with recurrent/stage IV breast cancer are discussed in this article.

Publisher

Harborside Press, LLC

Subject

Oncology

Cited by 605 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advancements in nanoconstructs for the theranostics applications for triple negative breast cancer;Journal of Drug Delivery Science and Technology;2024-03

2. Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer;Breast Cancer Research and Treatment;2024-02-04

3. Diagnostic yield of contrast-enhanced abdominal staging CT in patients with initially diagnosed breast cancer;European Journal of Radiology;2024-02

4. The prognostic potential of mammographic growth rate of invasive breast cancer in the Nijmegen breast cancer screening cohort;Journal of Medical Screening;2024-01-31

5. Rethinking surgical revisions: impact of the MonarchE trial on axillary dissection in hormone-positive HER2-negative early breast cancer patients potentially eligible for abemaciclib;British Journal of Cancer;2024-01-27